Company intelligence / Profile preview

SELP

Raleigh, North Carolina, United Statesselp.fr ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

SelSym Biotech is developing innovative hemostatic therapeutics, including a synthetic platelet product ("SymClot") and advanced hydrogels for wound healing. The company is preparing for IND submission within the next two years and has not yet entered clinical trials.

Therapeutic areas: Infectious DiseasesDermatologyHematology
Modalities: Synthetic platelet technologyHydrogel-based drug delivery therapyPolymer-drug conjugate therapy
Industry: Biotech

Beyond the preview

Go deeper on SELP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SELP.

Explore the full profile